Birdwatch Archive

Birdwatch Note

2024-10-06 13:01:57 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

コスタイベ(レプリコン)の安全性と有効性は治験で良好と評価されています。 死亡はプラセボ群が16(うち、新型コロナ9)接種群では5(うち、新型コロナ1)と減少しており、特段の懸念は認められません https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001266060.pdf 従来型についても、日本を含めた世界中の継続かつ徹底した科学的検証でワクチンによる被害は全くないか、極めて稀である可能性が高いと言えます https://www.mhlw.go.jp/content/10900000/000796742.pdf https://www.niid.go.jp/niid/ja/others.html https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines-safety https://doi.org/10.1016/S1473-3099(22)00320-6 https://warp.ndl.go.jp/info:ndljp/pid/13123205/www.cov19-vaccine.mhlw.go.jp/qa/0081.html https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#29 https://www.mhlw.go.jp/stf/shingi/shingi-kousei_284075.html ただし、1億回に1人程度の被害がないとまでは言い切れません。 IF値の高い医学誌・科学誌の査読済論文、WHOや先進国民主主義の政府機関の公式発表等の原典を参照しましょう。 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#34 https://togetter.com/li/2416068 https://togetter.com/li/2131189 https://togetter.com/li/2174198

Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1842730376445452663

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1842913184065429748
  • noteId - 1842913184065429748
  • participantId -
  • noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
  • createdAtMillis - 1728219717410
  • tweetId - 1842730376445452663
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 0
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 1
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • コスタイベ(レプリコン)の安全性と有効性は治験で良好と評価されています。 死亡はプラセボ群が16(うち、新型コロナ9)接種群では5(うち、新型コロナ1)と減少しており、特段の懸念は認められません https://doi.org/10.1038/s41467-024-47905-1 https://www.mhlw.go.jp/content/10906000/001266060.pdf 従来型についても、日本を含めた世界中の継続かつ徹底した科学的検証でワクチンによる被害は全くないか、極めて稀である可能性が高いと言えます https://www.mhlw.go.jp/content/10900000/000796742.pdf https://www.niid.go.jp/niid/ja/others.html https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines-safety https://doi.org/10.1016/S1473-3099(22)00320-6 https://warp.ndl.go.jp/info:ndljp/pid/13123205/www.cov19-vaccine.mhlw.go.jp/qa/0081.html https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#29 https://www.mhlw.go.jp/stf/shingi/shingi-kousei_284075.html ただし、1億回に1人程度の被害がないとまでは言い切れません。 IF値の高い医学誌・科学誌の査読済論文、WHOや先進国民主主義の政府機関の公式発表等の原典を参照しましょう。 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#34 https://togetter.com/li/2416068 https://togetter.com/li/2131189 https://togetter.com/li/2174198

Note Ratings

rated at rated by
2024-10-21 12:27:56 -0500 Rating Details
2024-10-07 04:29:30 -0500 Rating Details
2024-10-06 19:44:59 -0500 Rating Details
2024-10-06 17:09:53 -0500 Rating Details
2024-10-06 16:34:44 -0500 Rating Details
2024-10-06 16:09:42 -0500 Rating Details
2024-10-06 13:16:26 -0500 Rating Details
2024-10-06 11:43:46 -0500 Rating Details
2024-10-06 10:34:57 -0500 Rating Details
2024-10-06 09:33:49 -0500 Rating Details
2024-10-06 09:08:01 -0500 Rating Details
2024-10-06 08:57:27 -0500 Rating Details
2024-10-06 08:45:12 -0500 Rating Details
2024-10-06 08:31:15 -0500 Rating Details
2024-10-06 08:25:54 -0500 Rating Details
2024-10-07 21:58:34 -0500 Rating Details
2024-10-07 11:30:54 -0500 Rating Details
2024-10-07 08:37:36 -0500 Rating Details
2024-10-07 07:17:18 -0500 Rating Details
2024-10-07 05:46:30 -0500 Rating Details
2024-10-06 20:00:49 -0500 Rating Details
2024-10-06 19:44:39 -0500 Rating Details
2024-10-06 13:11:24 -0500 Rating Details
2024-10-06 09:49:43 -0500 Rating Details
2024-10-06 09:34:25 -0500 Rating Details
2024-10-06 09:15:38 -0500 Rating Details
2024-10-06 08:38:25 -0500 Rating Details
2024-10-06 08:14:26 -0500 Rating Details
2024-10-11 03:14:38 -0500 Rating Details
2024-10-07 19:10:39 -0500 Rating Details
2024-10-07 17:39:51 -0500 Rating Details
2024-10-07 08:58:35 -0500 Rating Details
2024-10-07 01:26:35 -0500 Rating Details
2024-10-07 00:46:21 -0500 Rating Details
2024-10-06 22:03:30 -0500 Rating Details
2024-10-06 18:02:19 -0500 Rating Details
2024-10-06 17:59:52 -0500 Rating Details
2024-10-06 17:26:08 -0500 Rating Details
2024-10-06 17:18:46 -0500 Rating Details
2024-10-06 16:04:59 -0500 Rating Details
2024-10-06 13:10:55 -0500 Rating Details
2024-10-06 13:02:26 -0500 Rating Details
2024-10-06 12:04:35 -0500 Rating Details
2024-10-06 11:43:38 -0500 Rating Details
2024-10-06 10:56:30 -0500 Rating Details
2024-10-06 10:42:12 -0500 Rating Details
2024-10-06 10:18:47 -0500 Rating Details
2024-10-06 10:01:31 -0500 Rating Details
2024-10-06 09:56:05 -0500 Rating Details
2024-10-06 09:52:52 -0500 Rating Details
2024-10-06 08:25:51 -0500 Rating Details
2024-11-02 04:34:36 -0500 Rating Details
2024-10-08 22:59:33 -0500 Rating Details
2024-10-10 12:04:23 -0500 Rating Details